当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Biological feasibility and importance of a gonorrhea vaccine for global public health.

Biological feasibility and importance of a gonorrhea vaccine for global public health.

Abstract：

:There is a growing public health interest in controlling sexually transmitted infections (STIs) through vaccination due to increasing recognition of the global disease burden of STIs and the role of STIs in women's reproductive health, adverse pregnancy outcomes, and the health and well-being of neonates. Neisseria gonorrhoeae has historically challenged vaccine development through the expression of phase and antigenically variable surface molecules and its capacity to cause repeated infections without inducing protective immunity. An estimated 78 million new N. gonorrhoeae infections occur annually and the greatest disease burden is carried by low- and middle-income countries (LMIC). Current control measures are clearly inadequate and threatened by the rapid emergence of antibiotic resistance. The gonococcus now holds the status of "super-bug" as there is currently no single reliable monotherapy for empirical treatment of gonorrhea. The problem of antibiotic resistance has elevated treatment costs and necessitated the establishment of large surveillance programs to track the spread of resistant strains. Here we review the need for a gonorrhea vaccine with respect to global disease burden and related socioeconomic and treatment costs, with an emphasis on the impact of gonorrhea on women and newborns. We also highlight the challenge of estimating the impact of a gonorrhea vaccine due to the need for more data on the burden of gonococcal pelvic inflammatory disease and related sequelae and of gonorrhea-associated adverse pregnancy outcomes and the problem of empirical diagnosis and treatment of STIs in LMIC. There is also a lack of clinical and basic science research in the area of gonococcal/chlamydia coinfection, which occurs in a high percentage of individuals with gonorrhea and should be considered when testing the efficacy of gonorrhea vaccines. Finally, we review recent research that suggests a gonorrhea vaccine is feasible and discuss challenges and research gaps in gonorrhea vaccine development.

journal_name

Vaccine

journal_title

Vaccine

authors

Vincent LR,Jerse AE

doi

10.1016/j.vaccine.2018.02.081

subject

Has Abstract

pub_date

2019-11-28 00:00:00

pages

7419-7426

issue

50

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)30278-0

journal_volume

37

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.

    abstract：PURPOSE:GEN-003 is a candidate therapeutic HSV-2 vaccine containing a fragment of infected cell protein 4 (ICP4.2), a deletion mutant of glycoprotein D2 (gD2ΔTMR), and Matrix-M2 adjuvant. In a dose-ranging phase 1/2a clinical trial, immunization with GEN-003 reduced viral shedding and the percentage of reported herpeti...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2016.09.001

    authors： Flechtner JB,Long D,Larson S,Clemens V,Baccari A,Kien L,Chan J,Skoberne M,Brudner M,Hetherington S

    更新日期：2016-10-17 00:00:00

  • Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B.

    abstract：:We have shown previously that expression library immunization is viable alternative approach to induce protective immunity against Neisseria meningitidis serogroup B. In this study we report that few rounds of library screening allow identification of protective pools of defined antigens. A previously reported protect...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.04.084

    authors： Yero D,Pajón R,Pérez Y,Fariñas M,Cobas K,Diaz D,Solis RL,Acosta A,Brookes C,Taylor S,Gorringe A

    更新日期：2007-07-09 00:00:00

  • Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity.

    abstract：:Vaccines utilizing poorly immunogenic subunit antigens are dependent upon adjuvants to drive the appropriate T cell responses. In an effort to determine the ability of several adjuvants to promote cell-mediated immunity (CMI), we assessed delayed-type hypersensitivity (DTH) in mice inoculated with heat-killed Listeria...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(96)00199-5

    authors： Baldridge JR,Ward JR

    更新日期：1997-03-01 00:00:00

  • Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.

    abstract：BACKGROUND:The 2015/2016 influenza season was characterized in Europe by the circulation of A(H1N1)pdm09 clade 6B.1 and B/Victoria-lineage influenza viruses. The components of the vaccines used in the current and past two seasons in the Valencia region were similar but not well matched to the 2015/2016 dominant influen...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.10.100

    authors： Puig-Barberà J,Guglieri-López B,Tortajada-Girbés M,López-Labrador FX,Carballido-Fernández M,Mollar-Maseres J,Schwarz-Chavarri G,Baselga-Moreno V,Mira-Iglesias A,Díez-Domingo J,Valencia Hospital Network for the Study of Influenza, Res

    更新日期：2017-12-19 00:00:00

  • Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells.

    abstract：:Influenza B virus infections are mainly restricted to humans, which is partially caused by the inability of influenza B virus NS1 protein to counteract the innate immune response of other species. However, for cell culture-based influenza vaccine production non-human cells, such as Madin-Darby canine kidney (MDCK) cel...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.069

    authors： Frensing T,Seitz C,Heynisch B,Patzina C,Kochs G,Reichl U

    更新日期：2011-09-22 00:00:00

  • Neutralization epitopes on the antigenic domain II of the Orientia tsutsugamushi 56-kDa protein revealed by monoclonal antibodies.

    abstract：:Monoclonal antibodies (MoAbs) reactive with the authentic Orientia tsutsugamushi 56-kDa protein were generated. MoAb FS10 and FS15 showed in vitro, as well as, in vivo neutralizing activity upon O. tsutsugamushi infection. Deletion mutants of the gene for 56-kDa protein of O. tsutsugamushi Boryong were expressed to ma...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00167-5

    authors： Seong SY,Kim MK,Lee SM,Odgerel Z,Choi MS,Han TH,Kim IS,Kang JS,Lim BU

    更新日期：2000-08-15 00:00:00

  • Synthetic gonadotrophin-releasing hormone (GnRH) vaccines incorporating GnRH and synthetic T-helper epitopes.

    abstract：:A vaccine against the gonadotrophin-releasing hormone (GnRH) is being developed as an immunological method for treatment of prostatic hypertrophy, based on the observation that active immunization against GnRH leads to the production of anti-GnRH antibodies which results in the shrinkage of the prostate gland. We have...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(93)90077-b

    authors： Sad S,Chauhan VS,Arunan K,Raghupathy R

    更新日期：1993-01-01 00:00:00

  • A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations.

    abstract：AIMS:The study was designed to evaluate a novel cationic lipid DNA adjuvant (N3) and its function for HIV-1gp160/rev DNA plasmid delivered intranasally. The primary N3/HIV-DNA plasmid immunizations were boosted intranasally with a gp41 peptide in a anionic L3 adjuvant. This novel prime-boost strategy of mucosal immuniz...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.08.015

    authors： Hinkula J,Devito C,Zuber B,Benthin R,Ferreira D,Wahren B,Schröder U

    更新日期：2006-05-22 00:00:00

  • Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.

    abstract：:Cholera is a potentially lethal diarrhea disease caused by the gram-negative bacterium Vibrio cholerae. The need for an effective cholera vaccine is clearly indicated but the challenges of eliciting both systemic and mucosal immune responses remains a significant challenge. In the current report, we discovered that a ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.04.008

    authors： Xu G,Wang S,Zhuang L,Hackett A,Gu L,Zhang L,Zhang C,Wang H,Huang Z,Lu S

    更新日期：2009-06-12 00:00:00

  • Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis.

    abstract：:Chlamydia trachomatis infections can occur early in life and may result in long-term sequelae. To assess the feasibility of implementing a vaccine in newborns, groups of 2-day-old BALB/c mice were immunized intranasally (i.n.) with 1x10(4) inclusion forming units (IFU) of C. trachomatis mouse pneumonitis (MoPn). As a ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.06.026

    authors： Pal S,Peterson EM,de la Maza LM

    更新日期：2005-11-16 00:00:00

  • Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus.

    abstract：:Dromedary camel hepatitis E virus is a novel HEV that belongs to the family Hepeviridae, and is classified as genotype 7 HEV (HEV-7). Since HEV-7 is transmitted from camels to humans and causes acute hepatitis E, this virus is a non-negligible pathogen for zoonosis, and a vaccine against HEV-7 infection is urgently ne...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.09.036

    authors： Guo Y,Yang F,Xu X,Feng M,Liao Y,He Z,Takeda N,Muramatsu M,Li Q,Li TC

    更新日期：2020-10-27 00:00:00

  • Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.

    abstract：:Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We examined t...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2016.10.020

    authors： Tashani M,Alfelali M,Barasheed O,Alqahtani AS,Heron L,Wong M,Rashid H,Booy R

    更新日期：2016-11-21 00:00:00

  • Midwife attitudes: an important determinant of maternal postpartum pertussis booster vaccination.

    abstract：BACKGROUND:The study was designed to determine the feasibility of implementing routine dTpa vaccination in the maternity ward to new mothers and to assess midwives' attitudes toward pertussis booster vaccination, their perceived susceptibility and severity of pertussis in their patients' communities, the perceived barr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.049

    authors： Robbins SC,Leask J,Hayles EH,Sinn JK

    更新日期：2011-08-05 00:00:00

  • Vaccination of sheep against M. paratuberculosis: immune parameters and protective efficacy.

    abstract：:Johne's disease in ruminants is caused by the pathogenic bacterium Mycobacterium avium subspecies paratuberculosis (Map). Currently available Map commercial vaccines protect against clinical disease but not infection. In this study, the proprietary Johne's vaccine Neoparasec and an aqueous formulation of Map 316F (Aqu...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.vaccine.2005.05.031

    authors： Begg DJ,Griffin JF

    更新日期：2005-10-10 00:00:00

  • pH-sensitive carbonate apatite nanoparticles as DNA vaccine carriers enhance humoral and cellular immunity.

    abstract：:To demonstrate the potential of pH-sensitive carbonate apatite (CO₃Ap) nanoparticles as DNA vaccine carriers to enhance vaccination efficacy, we examined the humoral and cellular immune responses of C57BL/6 mice immunized with the plasmid expression vector pCI-neo encoding the full-length soluble ovalbumin (OVA) (pCI-...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.09.032

    authors： He P,Takeshima SN,Tada S,Akaike T,Ito Y,Aida Y

    更新日期：2014-10-29 00:00:00

  • Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets.

    abstract：:Codon-pair bias de-optimization (CPBD) of viruses involves re-writing viral genes using statistically underrepresented codon pairs, without any changes to the amino acid sequence or codon usage. Previously, this technology has been used to attenuate the influenza A/Puerto Rico/8/34 (H1N1) virus. The de-optimized virus...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.11.054

    authors： Broadbent AJ,Santos CP,Anafu A,Wimmer E,Mueller S,Subbarao K

    更新日期：2016-01-20 00:00:00

  • Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?

    abstract：:Outer membrane protein (OMP) vaccines are being developed against Neisseria meningitidis serogroup B which may provide protection against common circulating serotypes and serosubtypes in some countries. However, limited data is available in Europe from genosubtyping meningococci. We therefore undertook a retrospective...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00033-1

    authors： Clarke SC,Diggle MA,Mölling P,Unemo M,Olcén P

    更新日期：2003-06-02 00:00:00

  • Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: expression levels and immune response.

    abstract：:Pertactin/P.69, a surface-associated polypeptide antigen of Bordetella pertussis, was expressed in a Salmonella typhimurium aroA aroD vaccine strain, BRD509, using different expression systems, and the immune response in mice against these constructs was compared. Initially, Pertactin/P.69 was expressed on the surface...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(96)00036-9

    authors： Anderson R,Dougan G,Roberts M

    更新日期：1996-10-01 00:00:00

  • Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity.

    abstract：INTRODUCTION:The World Health Organization recommends that as part of the polio end-game strategy a dose of inactivated poliovirus vaccine (IPV) be introduced by the end of 2015 in all countries currently using only oral poliovirus vaccine (OPV). Administration of fractional dose (1/5 of full dose) IPV (fIPV) by intrad...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.06.071

    authors： Resik S,Tejeda A,Mach O,Sein C,Molodecky N,Jarrahian C,Saganic L,Zehrung D,Fonseca M,Diaz M,Alemany N,Garcia G,Hung LH,Martinez Y,Sutter RW

    更新日期：2015-10-26 00:00:00

  • In vitro analysis of the factors contributing to the antiviral state induced by a plasmid encoding the viral haemorrhagic septicaemia virus glycoprotein G in transfected trout cells.

    abstract：:We have found out that transfection of the RTG-2 cell line with the viral haemorrhagic septicaemia virus (VHSV) glycoprotein G (G(VHSV))-coding plasmid induces an anti-VHSV state, similar to that induced by poly I:C. Taking the advantage of the constitutive expression of toll-like receptor 9 gene (tlr9) in RTG-2 cells...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.11.021

    authors： Ortega-Villaizan M,Chico V,Martinez-Lopez A,Falco A,Perez L,Coll JM,Estepa A

    更新日期：2011-01-17 00:00:00

  • Efficacy of a novel inactivated Lawsonia intracellularis vaccine in pigs against experimental infection and under field conditions.

    abstract：:The efficacy of a novel inactivated Lawsonia intracellularis vaccine, Porcilis® Lawsonia, was compared to that of a commercially available live attenuated vaccine in three experimental vaccination-challenge studies in pigs. The efficacy of the new vaccine was further tested under field conditions on a farm with a hist...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.02.067

    authors： Jacobs AAC,Harks F,Hazenberg L,Hoeijmakers MJH,Nell T,Pel S,Segers RPAM

    更新日期：2019-04-03 00:00:00

  • Comparison of DNA application methods to reduce BRSV shedding in cattle.

    abstract：:We compared the protection afforded by three different DNA application methods against bovine respiratory syncytial virus (BRSV) infection in cattle. A synthetic gene that codes for the G protein of BRSV was inserted into a eukaryotic vector and was used in the vaccine. Intradermal (i.d.) application with a needleless...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00198-9

    authors： Schrijver RS,Langedijk JP,Keil GM,Middel WG,Maris-Veldhuis M,Van Oirschot JT,Rijsewijk FA

    更新日期：1998-01-01 00:00:00

  • Changes in prevalence of influenza vaccination and strength of association of factors predicting influenza vaccination over time--results of two population-based surveys.

    abstract：:Two cross-sectional population-based telephone surveys interviewed 877 and 1,103 respondents aged >or=65. When compared to the first survey, respondents of the second survey were more likely to have heard of influenza vaccination (IV) (adjusted OR=4.09), to have received IV (adjusted OR=2.04) or to have done so in the...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.09.047

    authors： Lau JT,Kim JH,Choi KC,Tsui HY,Yang X

    更新日期：2007-11-28 00:00:00

  • Is flu vaccination opt-out feasible? Evidence from vaccination programme implementers and managers in the English National Health Service.

    abstract：BACKGROUND:In 2018/19, English NHS trusts (NHSTs) implemented an 'opt-out' policy for seasonal flu vaccination in frontline healthcare workers (HCWs). HCWs declining the vaccination were asked to sign an opt-out form and provide a reason for their decision. In addition, HCWs working in higher risk hospital environments...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.04.026

    authors： Bell S,Chantler T,Paterson P,Mounier-Jack S

    更新日期：2020-05-27 00:00:00

  • Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

    abstract：:The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection p...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.04.058

    authors： Minke JM,Siger L,Cupillard L,Powers B,Bakonyi T,Boyum S,Nowotny N,Bowen R

    更新日期：2011-06-20 00:00:00

  • Evaluation of measles vaccination programme conducted in two separate health centres.

    abstract：:Measles vaccination programmes at two vaccination centres in Ibadan, Nigeria were evaluated using the following factors as indicators: type of vaccination centre, age at vaccination, titre of vaccine, economic, health and social status of vaccinee. There was a significant association between type of vaccination centre...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(92)90419-k

    authors： Onoja AL,Adu FD,Tomori O

    更新日期：1992-01-01 00:00:00

  • Distribution of adsorbed antigen in mono-valent and combination vaccines.

    abstract：:The distribution of alpha-casein, bovine serum albumin (BSA), myoglobin and recombinant protective antigen (rPA) in mono-valent and combination vaccines containing aluminum hydroxide adjuvant was studied by fluorescence microscopy and flow cytometry. Green and red fluorescent probes were conjugated to the antigens. Ad...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.10.040

    authors： Morefield GL,HogenEsch H,Robinson JP,Hem SL

    更新日期：2004-05-07 00:00:00

  • Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries.

    abstract：INTRODUCTION:Rotavirus infection mainly affects children under 5 years of age and causes 453,000 deaths annually throughout the world. Several countries in Latin America have introduced the rotavirus vaccine and the majority have epidemiological data to measure impact following vaccine introduction. OBJECTIVE:To asses...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2013.05.065

    authors： De Oliveira LH,Giglio N,Ciapponi A,García Martí S,Kuperman M,Sanwogou NJ,Ruiz-Matus C,Marinho de Sousa MF

    更新日期：2013-07-02 00:00:00

  • Development of an attenuated strain of chikungunya virus for use in vaccine production.

    abstract：:An attenuated chikungunya (CHIK) virus clone was developed for production of a live vaccine for human use. CHIK strain 15561 was subjected to 18 plaque-to-plaque passages in MRC-5 cultures before CHIK 181/clone 25 was selected as vaccine seed based on homogeneous small plaque size, suckling mouse avirulence, reduced m...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(86)90003-4

    authors： Levitt NH,Ramsburg HH,Hasty SE,Repik PM,Cole FE Jr,Lupton HW

    更新日期：1986-09-01 00:00:00

  • Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

    abstract：BACKGROUND:Shigellae cause severe disease in endemic countries, especially in children. Several efficacy trials have been conducted with candidate vaccines against Shigellae, but the lack of protection, the safety concerns, or manufacturing challenges hindered successful market approval. Conjugated vaccines have been s...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.06.102

    authors： Hatz CF,Bally B,Rohrer S,Steffen R,Kramme S,Siegrist CA,Wacker M,Alaimo C,Fonck VG

    更新日期：2015-08-26 00:00:00